Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Idarucizumab (Alias: BI 655075)

Catalog No. T82083 Copy Product Info
🥰Excellent
Idarucizumab, a humanized monoclonal antibody fragment, serves as the first reversal agent for direct oral anticoagulants (DOACs). It specifically neutralizes the effects of oral direct thrombin inhibitors, thereby restoring hemostasis [1].

Idarucizumab

Copy Product Info
🥰Excellent
Catalog No. T82083
Alias BI 655075

Idarucizumab, a humanized monoclonal antibody fragment, serves as the first reversal agent for direct oral anticoagulants (DOACs). It specifically neutralizes the effects of oral direct thrombin inhibitors, thereby restoring hemostasis [1].

Idarucizumab
Cas No. 1362509-93-0
Pack SizePriceUSA StockGlobal StockQuantity
1 mgInquiryInquiryInquiry
5 mgInquiryInquiryInquiry
In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Questions
TargetMol
View More

Product Introduction

Bioactivity
Description
Idarucizumab, a humanized monoclonal antibody fragment, serves as the first reversal agent for direct oral anticoagulants (DOACs). It specifically neutralizes the effects of oral direct thrombin inhibitors, thereby restoring hemostasis [1].
SynonymsBI 655075
Reactivity
Human
Application
FACS
Functional assay
Antibody Type
Monoclonal
FormulationSupplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition.
Endotoxin<1.0 EU/mg
Related Conjugates and Formulations
Conjucates
Unconjugated
Antigen Details
TargetDOACs
Chemical Properties
Cas No.1362509-93-0
Storage & Solubility Information
Storage-20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Calculator

  • Dilution Calculator
  • Reconstitution Calculator
Related Tags: buy Idarucizumab | purchase Idarucizumab | Idarucizumab cost | order Idarucizumab